Genetic Signatures 2024 AGM Highlights
Genetic Signatures 2024 AGM, held on 20th of November, warmly farewelled our highly respected and long serving Chair, Dr Nick Samaras, and welcomed Caroline Waldron as Chair. “Caroline Waldron, our incoming Chair, has worked closely with me to facilitate a smooth transition, and on behalf of the Board, I welcome her to the next chapter…
Read MoreA warm welcome to Allison Rossiter
Genetic Signatures’ CEO, Allison Rossiter, brings a distinguished career in healthcare. With a proven track record at Roche Diagnostics, she navigated complex strategic challenges to achieve notable success. Ms Rossiter’s vision and leadership will be invaluable to Genetic Signatures as we enter our next phase of growth. She is warmly welcomed by the team! Allison…
Read MoreGenetic Signatures Appoints Former Roche Diagnostics Executive Allison Rossiter as CEO
Genetic Signatures Limited [ASX:GSS] (“GSS” or the “Company”), a global molecular diagnostics company today announces that its Board of Directors has appointed Allison Rossiter, a highly experienced molecular diagnostics executive, to serve as CEO, based in Sydney, Australia. Ms Rossiter has extensive global experience in the diagnostics industry and since 2003 has held several senior…
Read MoreFDA Clears Genetic Signatures’ Molecular Diagnostic Solution for Gastrointestinal Parasites
A comprehensive and uniquely differentiated multiplex PCR test for gastrointestinal parasites Newtown, New South Wales, Australia, 4th Jun 2024 – Genetic Signatures Limited (ASX: GSS), a leader in molecular diagnostic solutions for infectious disease, announces United States (US) Food and Drug Administration (FDA) 510(k) clearance for its EasyScreen™ Gastrointestinal Parasite Detection Kit and GS1 automated…
Read MoreGenetic Signatures farewells long-standing CEO & Director, Dr. John Melki
Genetic Signatures shares a bittersweet moment as we bid farewell to Dr. John Melki, who has announced his decision to step down as CEO and Director after an illustrious 21 years of leadership. John possesses an extraordinary blend of qualities and skills that have not only inspired, but also motivated and guided our team through a…
Read MoreRecent Article from Sharecafe: Genetic Signatures Leverages New Screening Targets to EU and US Markets
A recent article published via Sharecafe discusses Genetic Signatures’ new syndromic EasyScreen™ targets for use in EU and US Markets. To read more Click link
Read MoreGenetic Signatures’ CEO Dr John Melki will be presenting ShareCafe Micro/Small Cap “Hidden Gems” webinar
Genetic Signatures’ CEO Dr John Melki will be presenting ShareCafe Micro/Small Cap “Hidden Gems” webinar to be held at 12.30 pm AEST on Friday, 12 February 2021. The webinar is free to join and participants are required to register in advance via the following link: https://us02web.zoom.us/webinar/register/WN_KHst7HftQdSiQwoL6y9ufg
Read MoreGenetic Signatures (ASX: GSS) Annual Report 2020
Genetic Signatures Annual Report 2020 released. Click link for more information.
Read MoreWatch ShareCafe’s Hidden Gems Webinar
Genetic Signatures’ CEO Dr John Melki presenting at ShareCafe webinar
Genetic Signatures’ CEO Dr John Melki will be presenting ShareCafe Micro/Small Cap “Hidden Gems” webinar to be held at 12.30 pm AEST on Friday, 28 August 2020. The webinar is free to join and participants are required to register in advance via the following link: https://us02web.zoom.us/webinar/register/WN_Mjb04hQtSY-nlSbLqWlpSw
Read More